España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Eisai Co
ESALF
OTCPK
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$29.75
At close: Nov 19, 4:11 PM EDT
$30.96
1.21
4.07%
After Hours: Nov 19, 4:11 PM EDT
Get Report
Comment
Eisai Co (ESALF) Forecast
News
Earnings
Eisai Co (ESALF) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Eisai Co (OTC:ESALF) Stock
Eisai Co Stock (OTC: ESALF)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, January 24, 2025
Merck/Eisai's Keytruda Plus Lenvima Regime Shows Mixed Data In Esophagus Cancer Study
Vandana Singh
Thursday, November 14, 2024
CHMP Recommends EU Approval For Eisai's Leqem...
Benzinga Newsdesk
Monday, September 16, 2024
Reported Saturday, Merck And Eisai's Phase 3 ...
Benzinga Newsdesk
Thursday, August 22, 2024
Biogen's Alzheimer's Drug Secures UK Approval, But An Independent Agency Does Not Recommend Reimbursement
Vandana Singh
Friday, July 26, 2024
Biogen/Eisai's Alzheimer's Drug Leqembi Gets 'No Go' From European Drug Regulator's Advisory Panel, Cites Serious Side Events
Vandana Singh
The Committee For Medicinal Products For Huma...
Benzinga Newsdesk
Tuesday, July 16, 2024
Bernie Sanders: 'Getting Sick In America Should Not Mean Going Bankrupt, Losing Your Home, Car, Or Life Savings'
Benzinga Neuro
Wednesday, July 03, 2024
Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst
Vandana Singh
Tuesday, June 11, 2024
Why Is Eli Lilly Stock Trading Higher Premarket Tuesday?
Shivani Kumaresan
Friday, March 22, 2024
European Medicines Agency Delays Approval Decision For Biogen-Eisai Partnered Alzheimer's Drug Lecanemab
Vandana Singh
Friday, December 08, 2023
Merck, Eisai Report Yet Another Failure For Keytruda Plus Lenvima Combo Trial, This Time In Endometrial Cancer
Vandana Singh
Merck, Eisai Announced That Phase 3 LEAP-001 ...
Benzinga Newsdesk
Friday, October 13, 2023
Improved Alzheimer's Diagnosis Access: CMS Expands Amyloid PET Scan Usage
Vandana Singh
Tuesday, October 10, 2023
LuMind CEO At Odds With Neurologists Over Alzheimer's Drugs Made By Biogen, Eli Lilly
Vandana Singh
Monday, September 25, 2023
Amazon Invests Up To $4B In ChatGPT Competitor, Hollywood Writers Accept Preliminary Deal, ChatGPT Challenges Siri And Alexa With Introduction Of Verbal Responses: Today's Top Stories
Vandana Singh
Japan's Regulatory Authority Approves Biogen/Eisai's Alzheimer Treatment Leqembi
Vandana Singh
Friday, September 22, 2023
Merck-Eisai Partnered Two Keytruda/Lenvima Combo Trials Flunk In Certain Types Of Lung Cancer
Vandana Singh
Merck, Eisai's Two Phase 3 Trials Evaluating ...
Benzinga Newsdesk
Friday, August 25, 2023
Merck/Eisai's Cancer Combo Therapy Ambition Dashed Once Again, Companies Throw Towel On Head & Neck Trial
Vandana Singh
Thursday, July 20, 2023
Eisai And Biogen Present Latest Analysis Of L...
Benzinga Newsdesk
Friday, July 07, 2023
Expanded Medicare Coverage For Biogen-Eisai's Leqembi Signals a Turning Point in Alzheimer's Treatment: Analysts
Vandana Singh
Biogen And Eisai Granted Traditional Approval...
Benzinga Newsdesk
Tuesday, June 13, 2023
Alzheimer's Drug Leqembi Faces Hurdles in Europe: Concerns Over Health Risks and Healthcare Resources
Vandana Singh
Monday, June 12, 2023
Prospects for Full Approval of Eisai and Biogen's Leqembi Shine Brighter after FDA Committee Vote
Vandana Singh
Thursday, June 08, 2023
Bernie Sanders Takes on High Costs of Alzheimer's Treatment Leqembi, Calls Price Tag 'Unconscionable'
Vandana Singh
FDA Signals Support for Eisai-Biogen Alzheimer's Drug Data Confirms Benefits For Complete Approval
Vandana Singh
Thursday, May 04, 2023
Analysts Say Eli Lilly's Donanemab In Alzheimer's Is Encouraging, Outline Potential Implications For Biogen
Vandana Singh
Friday, April 21, 2023
Will US Medicare Fully Cover Alzheimer's Drugs? Eli Lilly Thinks Yes!
Vandana Singh
Monday, April 10, 2023
Merck, Eisai Shelve Keytruda Plus Lenvima Combo Trial In Skin Cancer Setting, Disappoints In Certain Type Of Colorectal Cancer
Vandana Singh
Monday, April 03, 2023
National Institute on Aging Aims Building $300M Alzheimer's Research Database
Vandana Singh
Friday, March 31, 2023
Eisai-Biogen Highlights Additional Data From Recently Approved Alzheimer's Drug
Vandana Singh
Thursday, March 16, 2023
Alzheimer's Association Launches Grassroots Level Lobbying For Medicare Coverage Of Alzheimer's Treatments
Vandana Singh
Tuesday, March 14, 2023
Analyst Says Biogen-Eisai's Alzheimer's Treatment Leqembi Coverage Enables Access To Over $2.5B Market Opportunity
Vandana Singh
Monday, March 06, 2023
Eisai-Biogen Seek Complete FDA Approval For Its Second Alzheimer's Treatment
Vandana Singh
FDA Accepted Eisai-Biogen's Supplemental Biol...
Benzinga Newsdesk
Friday, January 06, 2023
FDA Approves Biogen's Second Alzheimer's Treatment Under Accelerated Pathway
Vandana Singh
Thursday, December 22, 2022
Biogen's Alzheimer's Antibody Might Have A Third Death Associated With
Vandana Singh
Tuesday, December 20, 2022
Catalyst Pharma Acquires US Rights To Eisai's Epilepsy Drug
Vandana Singh
Wednesday, November 30, 2022
Despite Safety Concerns, Analysts Are Bullish On Biogen's Second Alzheimer's Candidate
Vandana Singh
Open Questions On Safety Lingers After Eisai-Biogen's Detailed Lecanemab Data For Alzheimer's
Vandana Singh
Monday, November 28, 2022
Biogen's Potential Early Alzheimer's Treatment Sees Second Death Linked To It, Shares Fall
Vandana Singh
Monday, November 14, 2022
Roche's Alzheimer's Flop Trial Removes One Competitor, But Reimbursement Debate Lingers
Vandana Singh
Monday, October 10, 2022
Despite Advancement, Benefits From Alzheimer's Drugs May Be Limited, Say Researchers
Vandana Singh
Monday, September 12, 2022
Merck's Keytruda Combo Trial Fails To Meet Primary Goal In Liver Cancer
Vandana Singh
Thursday, August 25, 2022
Citi Is Bullish On This Large Pharma Stock On Upcoming Data Readout From Diabetes Candidate
Vandana Singh
Wednesday, August 03, 2022
Merck's Two Keytruda Combo Cancer Trials Miss Primary Goal
Vandana Singh
Wednesday, July 06, 2022
The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer's Drug Due In January, FDA Reviews Roche's Lymphoma Candidate, Rare Pediatric Tag For Kazia's Pediatric Brain Cancer Candidate
Vandana Singh
Tuesday, May 10, 2022
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Vandana Singh
Eisai - Biogen Seek Accelerated Approval For Their Second Alzheimer's Drug
Vandana Singh
Tuesday, March 22, 2022
Biogen, Eisai Unveil New Data On Another Alzheimer's Candidate, Lecanemab
Vandana Singh
Show More
